Water Island Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Water Island Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-571,247	Closed	-$105M	–	103
2021 Q2	$105M	Buy	571,247 +24,802	+5%	+$4.26M	5.54%	2
2021 Q1	$83.6M	Buy	546,445 +65,207	+14%	+$10.1M	5.1%	5
2020 Q4	$75.2M	Buy	+481,238	New	+$61.8M	5.3%	8

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Water Island Capital's ALXN Position: Q3 2021 in Review

Water Island Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 571,247 shares — an estimated $105M sold.

Water Island Capital first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $105M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Water Island Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Water Island Capital sold 571,247 Alexion Pharmaceuticals shares in Q3 2021, an estimated $105M.
Water Island Capital first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Water Island Capital's Alexion Pharmaceuticals position peaked at $105M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Water Island Capital's 13F filing for Q3 2021, filed 12 Nov 2021.